Cargando…
Chemotherapy Resistance Mechanisms in Advanced Skin Cancer
Melanoma is a most dangerous and deadly type of skin cancer, and considered intrinsically resistant to both radiotherapy and chemotherapy. It has become a major public health concern as the incidence of melanoma has been rising steadily over recent decades with a 5-year survival remaining less than...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379221/ https://www.ncbi.nlm.nih.gov/pubmed/28382191 http://dx.doi.org/10.4081/oncol.2017.326 |
_version_ | 1782519565228441600 |
---|---|
author | Kalal, Bhuvanesh Sukhlal Upadhya, Dinesh Pai, Vinitha Ramanath |
author_facet | Kalal, Bhuvanesh Sukhlal Upadhya, Dinesh Pai, Vinitha Ramanath |
author_sort | Kalal, Bhuvanesh Sukhlal |
collection | PubMed |
description | Melanoma is a most dangerous and deadly type of skin cancer, and considered intrinsically resistant to both radiotherapy and chemotherapy. It has become a major public health concern as the incidence of melanoma has been rising steadily over recent decades with a 5-year survival remaining less than 5%. Detection of the disease in early stage may be curable, but late stage metastatic disease that has spread to other organs has an extremely poor prognosis with a median survival of less than 10 months. Since metastatic melanoma is unresponsive to therapy that is currently available, research is now focused on different treatment strategies such as combinations of surgery, chemotherapy and radiotherapy. The molecular basis of resistance to chemotherapy seen in melanoma is multifactorial; defective drug transport system, altered apoptotic pathway, deregulation of apoptosis and/or changes in enzymatic systems that mediate cellular metabolic machinery. Understanding of alterations in molecular processes involved in drug resistance may help in developing new therapeutic approaches to treatment of malignant melanoma. |
format | Online Article Text |
id | pubmed-5379221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | PAGEPress Publications, Pavia, Italy |
record_format | MEDLINE/PubMed |
spelling | pubmed-53792212017-04-05 Chemotherapy Resistance Mechanisms in Advanced Skin Cancer Kalal, Bhuvanesh Sukhlal Upadhya, Dinesh Pai, Vinitha Ramanath Oncol Rev Review Melanoma is a most dangerous and deadly type of skin cancer, and considered intrinsically resistant to both radiotherapy and chemotherapy. It has become a major public health concern as the incidence of melanoma has been rising steadily over recent decades with a 5-year survival remaining less than 5%. Detection of the disease in early stage may be curable, but late stage metastatic disease that has spread to other organs has an extremely poor prognosis with a median survival of less than 10 months. Since metastatic melanoma is unresponsive to therapy that is currently available, research is now focused on different treatment strategies such as combinations of surgery, chemotherapy and radiotherapy. The molecular basis of resistance to chemotherapy seen in melanoma is multifactorial; defective drug transport system, altered apoptotic pathway, deregulation of apoptosis and/or changes in enzymatic systems that mediate cellular metabolic machinery. Understanding of alterations in molecular processes involved in drug resistance may help in developing new therapeutic approaches to treatment of malignant melanoma. PAGEPress Publications, Pavia, Italy 2017-03-24 /pmc/articles/PMC5379221/ /pubmed/28382191 http://dx.doi.org/10.4081/oncol.2017.326 Text en ©Copyright B.S. Kalal et al., 2017 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Kalal, Bhuvanesh Sukhlal Upadhya, Dinesh Pai, Vinitha Ramanath Chemotherapy Resistance Mechanisms in Advanced Skin Cancer |
title | Chemotherapy Resistance Mechanisms in Advanced Skin Cancer |
title_full | Chemotherapy Resistance Mechanisms in Advanced Skin Cancer |
title_fullStr | Chemotherapy Resistance Mechanisms in Advanced Skin Cancer |
title_full_unstemmed | Chemotherapy Resistance Mechanisms in Advanced Skin Cancer |
title_short | Chemotherapy Resistance Mechanisms in Advanced Skin Cancer |
title_sort | chemotherapy resistance mechanisms in advanced skin cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379221/ https://www.ncbi.nlm.nih.gov/pubmed/28382191 http://dx.doi.org/10.4081/oncol.2017.326 |
work_keys_str_mv | AT kalalbhuvaneshsukhlal chemotherapyresistancemechanismsinadvancedskincancer AT upadhyadinesh chemotherapyresistancemechanismsinadvancedskincancer AT paivinitharamanath chemotherapyresistancemechanismsinadvancedskincancer |